Copyright Reports & Markets. All rights reserved.

COVID-19 Impact on Global Alzheimers and Parkinsons Diseases Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Alzheimers and Parkinsons Diseases Revenue
  • 1.4 Market Analysis by Type
    • 1.4.1 Global Alzheimers and Parkinsons Diseases Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Alzheimers
    • 1.4.3 Parkinsons
  • 1.5 Market by Application
    • 1.5.1 Global Alzheimers and Parkinsons Diseases Market Share by Application: 2020 VS 2026
    • 1.5.2 Hospital
    • 1.5.3 Clinic
    • 1.5.4 Other
  • 1.6 Coronavirus Disease 2019 (Covid-19): Alzheimers and Parkinsons Diseases Industry Impact
    • 1.6.1 How the Covid-19 is Affecting the Alzheimers and Parkinsons Diseases Industry
      • 1.6.1.1 Alzheimers and Parkinsons Diseases Business Impact Assessment - Covid-19
      • 1.6.1.2 Supply Chain Challenges
      • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
    • 1.6.2 Market Trends and Alzheimers and Parkinsons Diseases Potential Opportunities in the COVID-19 Landscape
    • 1.6.3 Measures / Proposal against Covid-19
      • 1.6.3.1 Government Measures to Combat Covid-19 Impact
      • 1.6.3.2 Proposal for Alzheimers and Parkinsons Diseases Players to Combat Covid-19 Impact
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Global Growth Trends by Regions

  • 2.1 Alzheimers and Parkinsons Diseases Market Perspective (2015-2026)
  • 2.2 Alzheimers and Parkinsons Diseases Growth Trends by Regions
    • 2.2.1 Alzheimers and Parkinsons Diseases Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Alzheimers and Parkinsons Diseases Historic Market Share by Regions (2015-2020)
    • 2.2.3 Alzheimers and Parkinsons Diseases Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Alzheimers and Parkinsons Diseases Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Alzheimers and Parkinsons Diseases Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Alzheimers and Parkinsons Diseases Players by Market Size
    • 3.1.1 Global Top Alzheimers and Parkinsons Diseases Players by Revenue (2015-2020)
    • 3.1.2 Global Alzheimers and Parkinsons Diseases Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Alzheimers and Parkinsons Diseases Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Alzheimers and Parkinsons Diseases Market Concentration Ratio
    • 3.2.1 Global Alzheimers and Parkinsons Diseases Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Alzheimers and Parkinsons Diseases Revenue in 2019
  • 3.3 Alzheimers and Parkinsons Diseases Key Players Head office and Area Served
  • 3.4 Key Players Alzheimers and Parkinsons Diseases Product Solution and Service
  • 3.5 Date of Enter into Alzheimers and Parkinsons Diseases Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global Alzheimers and Parkinsons Diseases Historic Market Size by Type (2015-2020)
  • 4.2 Global Alzheimers and Parkinsons Diseases Forecasted Market Size by Type (2021-2026)

5 Alzheimers and Parkinsons Diseases Breakdown Data by Application (2015-2026)

  • 5.1 Global Alzheimers and Parkinsons Diseases Market Size by Application (2015-2020)
  • 5.2 Global Alzheimers and Parkinsons Diseases Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Alzheimers and Parkinsons Diseases Market Size (2015-2020)
  • 6.2 Alzheimers and Parkinsons Diseases Key Players in North America (2019-2020)
  • 6.3 North America Alzheimers and Parkinsons Diseases Market Size by Type (2015-2020)
  • 6.4 North America Alzheimers and Parkinsons Diseases Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Alzheimers and Parkinsons Diseases Market Size (2015-2020)
  • 7.2 Alzheimers and Parkinsons Diseases Key Players in Europe (2019-2020)
  • 7.3 Europe Alzheimers and Parkinsons Diseases Market Size by Type (2015-2020)
  • 7.4 Europe Alzheimers and Parkinsons Diseases Market Size by Application (2015-2020)

8 China

  • 8.1 China Alzheimers and Parkinsons Diseases Market Size (2015-2020)
  • 8.2 Alzheimers and Parkinsons Diseases Key Players in China (2019-2020)
  • 8.3 China Alzheimers and Parkinsons Diseases Market Size by Type (2015-2020)
  • 8.4 China Alzheimers and Parkinsons Diseases Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Alzheimers and Parkinsons Diseases Market Size (2015-2020)
  • 9.2 Alzheimers and Parkinsons Diseases Key Players in Japan (2019-2020)
  • 9.3 Japan Alzheimers and Parkinsons Diseases Market Size by Type (2015-2020)
  • 9.4 Japan Alzheimers and Parkinsons Diseases Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Alzheimers and Parkinsons Diseases Market Size (2015-2020)
  • 10.2 Alzheimers and Parkinsons Diseases Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Alzheimers and Parkinsons Diseases Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Alzheimers and Parkinsons Diseases Market Size by Application (2015-2020)

11 India

  • 11.1 India Alzheimers and Parkinsons Diseases Market Size (2015-2020)
  • 11.2 Alzheimers and Parkinsons Diseases Key Players in India (2019-2020)
  • 11.3 India Alzheimers and Parkinsons Diseases Market Size by Type (2015-2020)
  • 11.4 India Alzheimers and Parkinsons Diseases Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Alzheimers and Parkinsons Diseases Market Size (2015-2020)
  • 12.2 Alzheimers and Parkinsons Diseases Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Alzheimers and Parkinsons Diseases Market Size by Type (2015-2020)
  • 12.4 Central & South America Alzheimers and Parkinsons Diseases Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Hoffmann-La Roche
    • 13.1.1 Hoffmann-La Roche Company Details
    • 13.1.2 Hoffmann-La Roche Business Overview and Its Total Revenue
    • 13.1.3 Hoffmann-La Roche Alzheimers and Parkinsons Diseases Introduction
    • 13.1.4 Hoffmann-La Roche Revenue in Alzheimers and Parkinsons Diseases Business (2015-2020))
    • 13.1.5 Hoffmann-La Roche Recent Development
  • 13.2 Novartis
    • 13.2.1 Novartis Company Details
    • 13.2.2 Novartis Business Overview and Its Total Revenue
    • 13.2.3 Novartis Alzheimers and Parkinsons Diseases Introduction
    • 13.2.4 Novartis Revenue in Alzheimers and Parkinsons Diseases Business (2015-2020)
    • 13.2.5 Novartis Recent Development
  • 13.3 Pfizer
    • 13.3.1 Pfizer Company Details
    • 13.3.2 Pfizer Business Overview and Its Total Revenue
    • 13.3.3 Pfizer Alzheimers and Parkinsons Diseases Introduction
    • 13.3.4 Pfizer Revenue in Alzheimers and Parkinsons Diseases Business (2015-2020)
    • 13.3.5 Pfizer Recent Development
  • 13.4 Merck
    • 13.4.1 Merck Company Details
    • 13.4.2 Merck Business Overview and Its Total Revenue
    • 13.4.3 Merck Alzheimers and Parkinsons Diseases Introduction
    • 13.4.4 Merck Revenue in Alzheimers and Parkinsons Diseases Business (2015-2020)
    • 13.4.5 Merck Recent Development
  • 13.5 Eli Lilly
    • 13.5.1 Eli Lilly Company Details
    • 13.5.2 Eli Lilly Business Overview and Its Total Revenue
    • 13.5.3 Eli Lilly Alzheimers and Parkinsons Diseases Introduction
    • 13.5.4 Eli Lilly Revenue in Alzheimers and Parkinsons Diseases Business (2015-2020)
    • 13.5.5 Eli Lilly Recent Development
  • 13.6 Orion Pharma
    • 13.6.1 Orion Pharma Company Details
    • 13.6.2 Orion Pharma Business Overview and Its Total Revenue
    • 13.6.3 Orion Pharma Alzheimers and Parkinsons Diseases Introduction
    • 13.6.4 Orion Pharma Revenue in Alzheimers and Parkinsons Diseases Business (2015-2020)
    • 13.6.5 Orion Pharma Recent Development
  • 13.7 UCB
    • 13.7.1 UCB Company Details
    • 13.7.2 UCB Business Overview and Its Total Revenue
    • 13.7.3 UCB Alzheimers and Parkinsons Diseases Introduction
    • 13.7.4 UCB Revenue in Alzheimers and Parkinsons Diseases Business (2015-2020)
    • 13.7.5 UCB Recent Development
  • 13.8 AstraZeneca
    • 13.8.1 AstraZeneca Company Details
    • 13.8.2 AstraZeneca Business Overview and Its Total Revenue
    • 13.8.3 AstraZeneca Alzheimers and Parkinsons Diseases Introduction
    • 13.8.4 AstraZeneca Revenue in Alzheimers and Parkinsons Diseases Business (2015-2020)
    • 13.8.5 AstraZeneca Recent Development
  • 13.9 Biogen
    • 13.9.1 Biogen Company Details
    • 13.9.2 Biogen Business Overview and Its Total Revenue
    • 13.9.3 Biogen Alzheimers and Parkinsons Diseases Introduction
    • 13.9.4 Biogen Revenue in Alzheimers and Parkinsons Diseases Business (2015-2020)
    • 13.9.5 Biogen Recent Development
  • 13.10 Teva Pharmaceutical Industries
    • 13.10.1 Teva Pharmaceutical Industries Company Details
    • 13.10.2 Teva Pharmaceutical Industries Business Overview and Its Total Revenue
    • 13.10.3 Teva Pharmaceutical Industries Alzheimers and Parkinsons Diseases Introduction
    • 13.10.4 Teva Pharmaceutical Industries Revenue in Alzheimers and Parkinsons Diseases Business (2015-2020)
    • 13.10.5 Teva Pharmaceutical Industries Recent Development
  • 13.11 AbbVie
    • 10.11.1 AbbVie Company Details
    • 10.11.2 AbbVie Business Overview and Its Total Revenue
    • 10.11.3 AbbVie Alzheimers and Parkinsons Diseases Introduction
    • 10.11.4 AbbVie Revenue in Alzheimers and Parkinsons Diseases Business (2015-2020)
    • 10.11.5 AbbVie Recent Development
  • 13.12 Vertical Pharmaceuticals
    • 10.12.1 Vertical Pharmaceuticals Company Details
    • 10.12.2 Vertical Pharmaceuticals Business Overview and Its Total Revenue
    • 10.12.3 Vertical Pharmaceuticals Alzheimers and Parkinsons Diseases Introduction
    • 10.12.4 Vertical Pharmaceuticals Revenue in Alzheimers and Parkinsons Diseases Business (2015-2020)
    • 10.12.5 Vertical Pharmaceuticals Recent Development
  • 13.13 ALLERGAN
    • 10.13.1 ALLERGAN Company Details
    • 10.13.2 ALLERGAN Business Overview and Its Total Revenue
    • 10.13.3 ALLERGAN Alzheimers and Parkinsons Diseases Introduction
    • 10.13.4 ALLERGAN Revenue in Alzheimers and Parkinsons Diseases Business (2015-2020)
    • 10.13.5 ALLERGAN Recent Development
  • 13.14 ACADIA Pharmaceuticals
    • 10.14.1 ACADIA Pharmaceuticals Company Details
    • 10.14.2 ACADIA Pharmaceuticals Business Overview and Its Total Revenue
    • 10.14.3 ACADIA Pharmaceuticals Alzheimers and Parkinsons Diseases Introduction
    • 10.14.4 ACADIA Pharmaceuticals Revenue in Alzheimers and Parkinsons Diseases Business (2015-2020)
    • 10.14.5 ACADIA Pharmaceuticals Recent Development
  • 13.15 Impax Laboratories
    • 10.15.1 Impax Laboratories Company Details
    • 10.15.2 Impax Laboratories Business Overview and Its Total Revenue
    • 10.15.3 Impax Laboratories Alzheimers and Parkinsons Diseases Introduction
    • 10.15.4 Impax Laboratories Revenue in Alzheimers and Parkinsons Diseases Business (2015-2020)
    • 10.15.5 Impax Laboratories Recent Development
  • 13.16 GE healthcare
    • 10.16.1 GE healthcare Company Details
    • 10.16.2 GE healthcare Business Overview and Its Total Revenue
    • 10.16.3 GE healthcare Alzheimers and Parkinsons Diseases Introduction
    • 10.16.4 GE healthcare Revenue in Alzheimers and Parkinsons Diseases Business (2015-2020)
    • 10.16.5 GE healthcare Recent Development
  • 13.17 VTV Therapeutics
    • 10.17.1 VTV Therapeutics Company Details
    • 10.17.2 VTV Therapeutics Business Overview and Its Total Revenue
    • 10.17.3 VTV Therapeutics Alzheimers and Parkinsons Diseases Introduction
    • 10.17.4 VTV Therapeutics Revenue in Alzheimers and Parkinsons Diseases Business (2015-2020)
    • 10.17.5 VTV Therapeutics Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    This report focuses on the global Alzheimers and Parkinsons Diseases status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Alzheimers and Parkinsons Diseases development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

    The key players covered in this study
    Hoffmann-La Roche
    Novartis
    Pfizer
    Merck
    Eli Lilly
    Orion Pharma
    UCB
    AstraZeneca
    Biogen
    Teva Pharmaceutical Industries
    AbbVie
    Vertical Pharmaceuticals
    ALLERGAN
    ACADIA Pharmaceuticals
    Impax Laboratories
    GE healthcare
    VTV Therapeutics

    Market segment by Type, the product can be split into
    Alzheimers
    Parkinsons
    Market segment by Application, split into
    Hospital
    Clinic
    Other

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    The study objectives of this report are:
    To analyze global Alzheimers and Parkinsons Diseases status, future forecast, growth opportunity, key market and key players.
    To present the Alzheimers and Parkinsons Diseases development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
    To strategically profile the key players and comprehensively analyze their development plan and strategies.
    To define, describe and forecast the market by type, market and key regions.

    In this study, the years considered to estimate the market size of Alzheimers and Parkinsons Diseases are as follows:
    History Year: 2015-2019
    Base Year: 2019
    Estimated Year: 2020
    Forecast Year 2020 to 2026
    For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

    Buy now